BioNTech to Close Facilities as COVID Demand Falls and Amgen Expands
Amgen plans to add US$300 million to expand US-based biologicals manufacturing in Puerto Rico. In contrast, BioNTech is consolidating production by closing multiple manufacturing sites in Germany and finishing its Singapore exit, impacting about 1,860 jobs. The moves reflect declining COVID-19 vaccine demand, excess capacity, and a shift of vaccine manufacturing responsibilities to partner Pfizer amid a pivot toward oncology.